semaglutide health canada approves 1st generic version of Ozempic in the country 1st generic version of Ozempic

Trend Change Driven by Fiscal Concerns Rising drug costs appear to be the main driver of the trend change on GLP-1s, with nearly two-thirds of states that responded to the KFF survey reporting that cost was a key factor contributing to their obesity drug coverage decision. California, which is facing an $18 billion budget deficit, projected its costs for covering GLP-1 drugs for obesity would quadruple to $790 million per year by the 2028-29 fiscal year if it didnt stop covering the drugs for that use under Medi-Cal

The staff believes that although diet and exercise will always be extremely important, the use of medication for both appetite and craving control can be necessary for a large number of patients

A Clearer Next Step When you understand how glutathione works inside the body, the treatment becomes easier to evaluate

Best for doses that require 15-50 units